Ms. Jennifer CheManaging Director

  • US Patent Attorney
  • Juris Doctor from Suffolk University Law School in Boston (2007)
  • S.B. in Chemistry from Massachusetts Institute of Technology (1998)

Jennifer is a US Patent Attorney with a deep, multi-faceted understanding of the biopharmaceutical industry. She has a strong track record of driving creative and unique global IP strategies for various types of products, research collaborations and business development deals. Having worked as a scientist, patent attorney, and executive over her 20-year career, Jennifer has a deep appreciation and understanding for how to devise IP strategies that take into account both the technical as well as the long-range business needs of an organization.

Jennifer spent over ten years at Vertex Pharmaceuticals, building up and overseeing global patent portfolios for small molecules developed at the company’s UK and Canada R&D sites in oncology and GI diseases. Prior to joining Eagle IP, Jennifer was Vice President of IP and Legal Affairs at Axcella Therapeutics, a Flagship Pioneering originated startup focused on addressing metabolic dysregulation by leveraging amino acid biology.

Jennifer has a strong scientific foundation, from her chemistry degree at MIT to her six years working as a medicinal chemist in drug discovery at Takeda Oncology (formerly Millennium Pharmaceuticals).

Jennifer is a well-recognized speaker and is regularly invited to give talks in Hong Kong (HKU, CUHK, HKUST, HK Science Park, MIT Innovation Node), and around the world (US, Europe). She writes regularly on patent law issues, and is the founder and author of the blog

Jennifer advises clients on IP strategy, IP portfolio management, global patent strategy, patent preparation and prosecution, drug protection strategies, IP ownership, trade secrets, and more. Her areas of expertise include pharmaceuticals, biotechnology, drug discovery and development, biochemistry, small molecules, large molecules, chemistry, formulations, medicine, drug-delivery systems, and nanotechnology-based therapeutics in a broad range of disease areas.

Her working languages are English and Mandarin Chinese.